ATHE Alterity Therapeutics Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ATHE [NASD]

Alterity Therapeutics Limited

Healthcare | Biotechnology | Australia

statements

Index	-	P/E	-	EPS (ttm)	-0.64	Insider Own	18.70%	Shs Outstand	15.36M	Perf Week	-9.60%
Market Cap	38.20M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.34M	Perf Month	-10.04%
Income	-9.50M	PEG	-	EPS next Q	-	Inst Own	3.00%	Short Float	0.03%	Perf Quarter	20.93%
Sales	-	P/S	-	EPS this Y	25.00%	Inst Trans	-0.79%	Short Ratio	0.00	Perf Half Y	189.86%
Book/sh	0.33	P/B	5.53	EPS next Y	-	ROA	-92.10%	Target Price	-	Perf Year	58.79%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-117.50%	52W Range	0.28 - 5.15	Perf YTD	134.12%
Dividend	-	P/FCF	-	EPS past 5Y	-5.10%	ROI	-	52W High	-64.54%	Beta	1.54
Dividend %	-	Quick Ratio	3.60	Sales past 5Y	-	Gross Margin	-	52W Low	552.18%	ATR	0.16
Employees	12	Current Ratio	3.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.73	Volatility	9.31% 7.45%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	2.90%	Profit Margin	-	Rel Volume	0.06	Prev Close	1.91
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.06M	Price	1.83
Recom	-	SMA20	-12.02%	SMA50	-18.75%	SMA200	56.23%	Volume	117,931	Change	-4.39%

Aug-05-20 03:10PM	Why Alterity's Stock Is Trading Lower Today Benzinga -15.16%
Aug-04-20 09:07AM	Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's MarketWatch +154.07%
02:33AM	Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug Benzinga
Aug-03-20 09:33PM	New data independently confirms and extends laboratory findings and expands safety profile of ATH434 PR Newswire -7.53%
Jul-30-20 06:49PM	Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report PR Newswire
Jul-01-20 08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga +57.14%
Jun-29-20 11:14PM	Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 PR Newswire
May-20-20 08:58PM	Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology PR Newswire
Apr-30-20 04:35AM	Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report PR Newswire
Apr-21-20 05:50PM	How Should Investors React To Alterity Therapeutics Limited's (ASX:ATH) CEO Pay? Simply Wall St.
Feb-21-20 07:15PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 86% Share Price Drop Simply Wall St. -5.21%
Nov-11-19 10:30PM	Companies Like Alterity Therapeutics (ASX:ATH) Can Be Considered Quite Risky Simply Wall St.
Sep-12-19 11:07PM	Does Alterity Therapeutics Limited's (ASX:ATH) CEO Salary Reflect Performance? Simply Wall St.
Jul-29-19 08:00AM	Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial Business Wire
Jul-11-19 09:31PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 89% Share Price Drop Simply Wall St. -6.30%
May-06-19 08:00AM	Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting Business Wire -5.38%
May-03-19 08:00AM	Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting Business Wire +14.81%

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience